By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

Agonists Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering. The Europe glucagon-like peptide-1 (GLP-1) agonists ...